ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Canaccord Genuity 30th Annual Growth Conference on Thursday, August 12, 2010 at 8:00 a.m. EDT. The conference is being held at The Intercontinental Hotel in Boston, Massachusetts. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com. Shortly following the live webcast a replay will also be available on the Company website.
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines.
For additional information about the Company, please visit www.inhibitex.com.
KEYWORDS: United States North America Georgia
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Infectious Diseases Pharmaceutical